{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=123I-metaiodobenzylguanidine", "query": { "intervention": "123I-metaiodobenzylguanidine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=123I-metaiodobenzylguanidine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T21:10:56.994Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00028106", "title": "131MIBG to Treat Malignant Pheochromocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma" ], "interventions": [ { "name": "[131]I-MIBG", "type": "DRUG" }, { "name": "6-[18F]Fluorodopamine", "type": "DRUG" }, { "name": "[123]I-MIBG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 32, "start_date": "2001-12-05", "completion_date": "2007-01-08", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028106" }, { "nct_id": "NCT03126916", "title": "Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ganglioneuroblastoma", "Ganglioneuroblastoma, Nodular", "Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Iobenguane I-123", "type": "RADIATION" }, { "name": "Iobenguane I-131", "type": "RADIATION" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan Hydrochloride", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "30 Years", "sex": "ALL", "summary": "365 Days to 30 Years" }, "enrollment_count": 750, "start_date": "2018-05-14", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126916" }, { "nct_id": "NCT01250912", "title": "Imaging With a Radio Tracer to Guide VT Ablations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ventricular Tachycardia", "Arrhythmia" ], "interventions": [ { "name": "123I-metaiodobenzylguanidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2010-03", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2022-01-27", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01250912" }, { "nct_id": "NCT00126438", "title": "Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure, Congestive" ], "interventions": [ { "name": "123I-mIBG (meta-iodobenzylguanidine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2005-07", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126438" }, { "nct_id": "NCT01432626", "title": "Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress Induced Cardiomyopathy" ], "interventions": [ { "name": "I-123 radiolabeled metaiodobenzylguanidine cardiac imaging", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01432626" }, { "nct_id": "NCT01522378", "title": "Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Congestive Heart Failure" ], "interventions": [ { "name": "123 iodine metaiodobenzylguanidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2012-02", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522378" }, { "nct_id": "NCT00126425", "title": "Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure, Congestive" ], "interventions": [ { "name": "123I-mIBG (meta-iodobenzylguanidine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 587, "start_date": "2005-07", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2016-12-13", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126425" }, { "nct_id": "NCT02279030", "title": "Use of MIBG Scan Images in PVC Ablations", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Premature Ventricular Contractions" ], "interventions": [ { "name": "MIBG nuclear scan", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-06", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279030" }, { "nct_id": "NCT04510311", "title": "Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "3-[18F]Fluoro-para-hydroxyphenethylguanidine", "type": "DRUG" }, { "name": "[123I] metaiodobenzylguanidine", "type": "DRUG" }, { "name": "Positron emission tomography/computed tomography scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Planar scintigraphy scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Single photon emission computed tomography/computed tomography scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-10-19", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510311" }, { "nct_id": "NCT04385277", "title": "Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ganglioneuroblastoma, Nodular", "Neuroblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Iobenguane I-123", "type": "RADIATION" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 41, "start_date": "2020-12-31", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-07T21:10:56.994Z", "location_count": 70, "location_summary": "Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04385277" } ] }